Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025
What macro or sector factors could amplify or dampen the stock's reaction to the Phase 3 results?
How does the current earnings performance compare to prior quarters and what does that imply for cash runway ahead of the data readout?
Are there any contingent financing or partnership arrangements tied to the Phase 3 outcomes that could influence the stock?
27 days ago